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a b s t r a c t
Corticobasal [116_TD$DIFF] egeneration Degeneration (CBD) and Progressive Supranuclear Palsy (PSP) are
types of four repeats (4R) tauopathies, which are associated to parkinsonian syndromes. The
aim of the work is to analyze cases of patients of the Department of Neurology, overlapping
of syndromes related to both pathologies and to show that most likely CBS and PSP are not
lineary related to their commonly associated syndromes i.e. adequately corticobasal syn-
dromes and progressive supranuclear palsy syndromes. In the context of each patient
factors in favor of most likely CBS, PSP or both diseases are discussed and analyzed using
contemporary criteria. This work discusses multidimensional aspect of the examination of
ﬁve patient aged 64 to 83 – 4 females and 1 male with 4R tauopathies and difﬁculties in
distinguishing both diseases. The duration of the disease varied from 1 to 5 years. Each
patient after neurological examination was assessed using magnetic resonance imaging
(MRI) and psychological test. Examination of all patients was extended using single photon
emission computer tomography (SPECT) to reveal the usefulness of this tool in differentia-
tion of diseases was done. The outcome of this examination was veriﬁed with prior clinical
manifestation of patients andmorphological abnormalities inmagnetic resonance imaging.
Autopsies were not conducted.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.1. IntroductionCorticobasal degeneration (CBD) and progressive supranuclear
palsy (PSP) belong to atypical parkinsonisms (APS) which
due to their histopathology are deﬁned as primary tauopathies
[117_TD$DIFF] 1–7]. In the classiﬁcation of tauopathies PSP and corticobasal
syndrome (CBS) are most commonly associated with tau* [114_TD$DIFF]Corresponding author at [115_TD$DIFF]: Department of Neurology, Medical Unive
E-mail address: Piotr.Alster@gmail.com (P. Alster).
https://doi.org/10.1016/j.pjnns.2018.06.002
0028-3843/© 2018 Polish Neurological Society. Published by Elsevier Sproteins containing four repeats (4R) of approximately 32
aminoacids in the microtubule binding domain [118_TD$DIFF] 1–3]. Never-
theless regarding the fact that CBS may be related to 4R
pathologies such as CBD and PSP, but also Alzheimer [119_TD$DIFF]'s disease
(AD) and Pick[120_TD$DIFF]'s disease which are associated with three
repeats tauopathies (3R), it should be stressed that CBS may
be a clinical manifestation of either 3R or 4R [121_TD$DIFF] 7]. It should also
be highlighted that ADmay be related to accumulation of bothrsity of Warsaw, Kondratowicza 8, 03-242 Warsaw, Poland.
p. z o.o. All rights reserved.
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logical differentiation between CBD/PSP and frontotemporal
lobar degeneration, which is related with three repeats (3R).
PSP and less common CBD were described in 1960s (PSP in
1964, CBD in 1968) [122_TD$DIFF] 4–7] as neurodegenerative diseases with
relatively short duration and rather difﬁcult differentiation
from each other and other extrapyramidal disorders [123_TD$DIFF] 4]. PSP
and CBD due to their similar symptomatology and pathology
are often mistaken with each other. Often patients have
symptoms characteristic for both diseases.
The aim of the study was to discuss whether strict
differentiation of most likely CBS and PSP is justiﬁed in all
cases. Clinical presentations were correlated with mental
dysfunction and neuroimaging.
2. Material and methodsFive patients with clinical symptoms combining CBS and PSP
were assessed. In this study generally accepted criteria of
diagnosis of CBD and PSP were used [124_TD$DIFF] 5,6] (Tables 1 and 2). The
presence and stage of ocular motor dysfunction, postural
instability, akinesia and cognitive dysfunction were used as
basic criteria of themost common subtype of PSP – Richardson
syndrome. The certainty of diagnosis was based on the in-
tensity of symptoms. (Table 1). CBD was examined by assess-
ing the presence and stage of apraxia, alien limb phenomena,
cortical sensory loss, cognitive impairment, behavioral
changes, and aphasia, asymmetric onset of levodopa-resistant
parkinsonism, dystonia, andmyoclonus. Themore symptoms
were present in the clinical examination, the more certain
the diagnosis was (Table 2). Symptoms of both diseases were
observed among all patients demonstrated in the study.
The inclusion and exclusion criteria of both diseases were
assessed. In this work 5 case studies of patients with
insufﬁcient symptomatology to diagnose either CBD or PSP
are demonstrated (Table S1). All of these patients were
















CBD-PSP * * *
Based on Ref. [108_TD$DIFF] 5].– (AF, DK). Psychological examinations were performed using
Montreal Cognitive Assessment (MoCA) or Mini Mental State
Examination (MMSE) and Frontal Assessment Battery (FAB).
Neuroimaging was performed using magnetic resonance
imaging (MRI) and single photon emission computer tomog-
raphy (SPECT). The project was approved by the Ethical
Committee of the Medical University of Warsaw – AKBE243/
2016.3. Study
3.1. Patient #1
A 82-year-old female patient was admitted to the Department
of Neurology in November of 2016. Since 2012, when she was
78 years old, the patient[125_TD$DIFF]'s family observed slowness of speech,
psychomotor slowness and falls. At the time of the examina-
tion the patient presented facialmasking, oculomotor apraxia,
paresis of the right upper and lower limb. Bradykinesia was
more visible on the right side of the body than on the left.
Patient presented more severe bradykinesia in lower limbs
than in upper ones, general psychomotor slowness, retro-
pulsion and lack of balancing during gait. The patient
complained of deterioration of handwriting, memory deﬁcits,
symptoms of orthostatic hypotension, constipation, dysuria
and abnormal sweating. Logopedic examination demonstrat-
ed bradylalic non-ﬂuent speech. The patient had difﬁculties in
initiation of speech. Nasal speech, dysprosody and echolalia
could also be observed. Psychological examination revealed
dementia of moderate intensity with apraxia, impaired
executive functions, impaired attention, deteriorated learning
and memory abilities. Posturography conﬁrmed static and
dynamic imbalance. MRI revealed slightly reduced volume of
the midbrain, medianus dimension (anterior–posterior) in the
midline approx. [126_TD$DIFF] 4 mm and slightly concave top surface, the
picture was not evident. SPECT highlighted irregular distribu-
tion of the radiopharmaceutic hexamethylpropyleneamine Orobuccal or limb apraxia
 Cortical sensory deﬁcit




1 of mentioned above
symptoms
–
2 of mentioned above
symptoms
–
* * – 3 of:
(a) axial or asymmetric






gaze palsy or decreased
velocity of vertical saccades
Table 2 – Progressive supranuclear palsy [109_TD$DIFF] 6].
Level of certainty Ocular motor
dysfunction
Postural instability Akinesia Cognitive dysfunction
1 (highest) Vertical supranuclear
gaze palsy
Repeated unprovoked





variant of primary progressive
aphasia or progressive apraxia
of speech
2 Slow velocity of vertical
saccades
Tendency to fall on the






3 (lowest) Frequent macro square
wave jerks or ‘‘eyelid
opening apraxia’’
More than two steps
backward on the





Based on Ref. [110_TD$DIFF] 6].
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HMPAO within the anterior part of parietal lobe and corpus
callosum on the left side. Signiﬁcant decrease in the
accumulation was observed within the basal ganglia, nucleus
caudatus on the left side, cerebellum on the left side and
thalamus bilaterally. Pattern of HMPAO distribution was
interpreted as resembling CBS. The patient also suffered due
to hypertension and diabetes type 2 ([127_TD$DIFF] mage 1).[(Image_1)TD$FIG]
Image 1 – (1.1) MRI – decreased volume of midbrain – Patient
#1. (1.2) SPECT – asymmetric decrease in blood flow –
Patient #1.3.2. Patient #2
A 65-year-old female patient presented ﬁve year history of
parkinsonian syndrome which began with bradykinesia at
the age of 60. After ﬁve years intensive rigidity on the right
side appeared. More brisk reﬂexes and Babinski sign on the
right could also be observed. Psychological examination
demonstrated disturbed episodic, operational and direct
memory and deﬁcits in executive functions. Logopedic
examination revealed bradylalia and non-ﬂuent speech. MRI
showeddisseminated small ischemic regions. Cortical atrophy
within the left parietal lobe was observed. MRI also indicated
cerebellar atrophy. SPECT imaging revealed limited accumu-
lation of radiotracer within the frontal lobe, mainly on the
left side. The patient did not suffer due to any other chronic
illness.
3.3. Patient #3
A 64-year-old male was admitted to the Department of
Neurology due to progressive speech disorders, cognitive
impairment, bradykinesia, paresis of right upper limb and
balance abnormalities. First symptoms appeared at the age of
59. In neurological examination the patient showed involun-
tary movement of the right upper limb. The speech was non-
ﬂuent due to dysarthria. The patient presented cognitive
impairment, bradykinesia and limitations in movements of
eyeballs in all directions, deliberative symptoms, bilateral
pyramidal syndrome, arrhythmia disturbance and widened
asymmetric gait. The logopedic examination conﬁrmed
aphasia and dysarthria. The neuropsychological study was
dominated by linguistic and frontal disorders. In stabilometric
tests gait imbalance was observed. After administration of [128_TD$DIFF]
200 mg of levodopa no effect on the neurological condition
was observed. MR scans revealed asymmetric cortical atrophy
mainly in the left lateral sulcus. Atrophy of mesencephalon
was also indicated. SPECT examination revealed reduced
accumulation of the radiopharmaceutic on the left side within
frontal superior and medium gyrus, temporal superior gyrus,
Rolandic operculum and insula. The image indicated that the
neurodegenerative deterioration might be due to CBS or PSP.
The patient also suffered due to vascular changes in the
central nervous system, acute pancreatitis in the past. He was
also addicted to alcohol.
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A 65-year-old female patient was admitted to the Department
of Neurology for further diagnosis of postural instability with
falls, bradykinesia and rigidity of left limbs. First symptoms
occurred at the age of 63. In neurological examination
cognitive impairment, dysarthria, hypomimia, bradykinesia,
hypokinesia more severe in the left limbs, massive rigidity of
the left limbs, postural disorders, gait dysfunction, clonuses,
bilateral Babinski symptom were observed. Neuropsychologi-
cal examination revealed dementia. MRI showed small
disseminated vascular changes. Moreover signs of marginal
cortical degeneration were observed. In SPECT 99mTc-HMPAO
examination a decrease in the accumulation of the radiotracer
was observed in the occipital lobe, insula and globus pallidus
on the left side. Simultaneously normal perfusion on both
sides of the thalamuswas observed. The patient suffered from
cognitive impairments, verbal disorders and hypertension and
cervical discopathy.
3.5. Patient #5
A 73-year-old female was admitted to the Department of
Neurology for extended diagnosis due to involuntary move-
ments within the face, gait disorders, slowness of movement
and deteriorating cognitive impairments, which began two
years before hospitalization and were followed after one year
by falls. The ﬁrst symptoms appeared at the age of 71. In
neurological examination hypokinesia, bradykinesia, rigidity
were more intensive on the right side, dystonia of the right
foot, cramp of left half of the face, dysarthria, abnormalities in
postural reﬂexes and limited vertical eye movement looking
down were found. MRI showed humming bird sign. No other
abnormalities in examination of mesencephalon and pons
where detected. SPECT 99mTc-HMPAO revealed decreased
accumulation within the left thalamus, left inferior parietal
gyrus, right cingulate and paracingulate, right thalamus, left
superior temporal gyrus, parietal lobe and left middle
cingulate and paracingulate. The patient also suffered due
to depression, hypertension and hypercholesterolemia.
4. DiscussionThe present case studies indicate that CBD and PSP share
similar symptoms. Therefore, their clinical differentiation
may be challenging for physicians. Both disorders share some
symptoms such as parkinsonian syndrome, aphasia and
progressive cognitive impairments. Other symptoms such as
asymmetry of symptoms may be subjective or could not
differentiate the diseases. These factors create a controversy,
whether to differentiate diseases based on clinical symptom-
atology or to diagnose a disease as most likely CBS variant PSP
ormost likely PSP variant CBS. Additionally symptoms such as
cognitive impairment or progressive dementia not only can be
associated with PSP and CBS, but also may be due to vascular
disorders which creates another difﬁculty in examination and
proper diagnosis.
In a study, in which 39 cases were analyzed, CBS was
associated with CBD pathology only in 55% of cases, in 20.5%with PSP pathology and in 7.2% with Pick[129_TD$DIFF]'s disease pathology
[7]. Thismay possibly lead to considering the clinical picture of
CBS as a marker of tauopathies. On the other hand both CBS
and PSP tend to have different histopathological basis.
Another study analyzed how CBS was associated with various
pathologies [130_TD$DIFF] 8]. It showed that in contrast with widespread
changes in AD pathology, PSP and CBD pathology with clinical
CBS was related preferably to more focal atrophies, predomi-
nantly within the premotor area.
It is stressed that unlike PSP, where clinical picture of PSP-
RS is highly predictive for PSP pathology, no clinical symptom
is predictive of CBD [131_TD$DIFF] 9]. Cases of corticobasal syndrome related
to AD pathology have also been recently presented [132_TD$DIFF] 10].
Among symptoms of corticobasal syndrome related to AD,
authors of that article present limb myoclonus, dressing
apraxia, memory loss, lower Mini Mental State Examination
results, cortical sensory loss, visuospatial difﬁculties, hemi-
sensory neglect and absence of limb rigidity. The study
stresses longer duration of the disease compared with CBS
associated with CBD pathology.
In CBS and PSP syndromes/Richardson[133_TD$DIFF]'s syndromes (PSPS/
RS) the clinical pictures quite often do not correlate with
respective CBD and PSP pathologies [134_TD$DIFF] 11]. Though one of the
studies showed greater tau load in mid-frontal and inferior-
parietal cortices in patients with PSP pathology and CBS
clinical manifestation (PSP-CBS) than PSP pathology and PSP-
RS. The same study presented similar severity of those
pathologies. It should also be highlighted that PSP-CBS is
one of many clinical presentations of PSP pathology such as
PSP parkinsonism (PSP-P), PSP with pure akinesia and gait
freezing (PSP-PAGF), PSP with behavioral variant of fronto-
temporal dementia (PSP-bvFTD) and PSP with primary non-
ﬂuent afasia (PSP-nfaPNFA) [135_TD$DIFF] 12] (Table S2). Moreover, vascular
pathology mimicking PSP with predominant lower body
involvement had been described [136_TD$DIFF] 13]. Among the types
mentioned above, PSP-RS with postural instability, supra-
nuclear gaze palsy and frontal dysfunction and PSP-P
associated with asymmetric onset, tremor and limited
response to levodopa are the most common. It should also
be stressed that some of the patients who never presented
ocular motor symptoms, are postmortem diagnosed with PSP [137_TD$DIFF]
[14]. Superior cerebellar peduncle, subthalamic nucleus atro-
phy and midbrain atrophy also known as humming bird sign
in MRI may be useful in differential diagnosis. However recent
research shows that midbrain atrophy is correlated with
clinical manifestation of PSP, patients with PSP pathology and
non-PSP symptomatology tend to not have reduced volume of
midbrain [138_TD$DIFF] 15]. Therefore researches also stress that humming
bird sign should not be perceived as an indicator of PSP
pathology [139_TD$DIFF] 15,16].
Histopathological differentiation criteria had been shown
in various studies [140_TD$DIFF] 17–23]. According to those perspectives, PSP
is preferably associated with tau-positive neuroﬁbrillary
tangles (NFT), coiled bodies, threads and tufted astrocytes [141_TD$DIFF]
[17]. The localization of NFT in PSP is related to subcortical and
brainstem nuclei and cerebellar dentate nucleus [142_TD$DIFF] 17,18].
Criteria specify the presence of pathological accumulation of
abnormally phosphorylated microtubule-associated domain
into ﬁlamentous deposits. In CBD, tau pathology affects both
neurons and glia and the typical ﬁndings include pretangles,
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factor may be interpreted ‘‘minimal pathological features of
CBD’’, among which can be mentioned cortical and striatal
tau-positive neuronal and glial lesions [141_TD$DIFF] 17]. This may be a
striking feature in the context of the growing number of
various clinical manifestations of CBD, which were pre-
mortem interpreted as PSP. A case study published in 2000
described a Japanese woman with gradually developing
parkinsonism [143_TD$DIFF] 23]. Gaze palsy, dementia and dystonia were
observed. Clinical manifestation was interpreted as PSP. The
woman died at the age of 71 of respiratory failure. Histopath-
ological examination of her brain revealed the presence of
astrocytic plaques and swollen achromatic neurons that
supported the diagnosis of CBD [143_TD$DIFF] 23]. It is stressed that due
to the similarities observed in the neuropathology of CBD and
PSP, more detailed analysis aiming to distinguish abnormal
tau inclusions may be necessary [144_TD$DIFF] 21]. This brings to a point
where differentiation between tufted astrocyted and astrocyt-
ic plaques becomes relevant [141_TD$DIFF] 17]. Thesemethods tend to be the
most speciﬁc ones in the context of differentiation of typical
manifestations of neuropathological CBD and PSP.
Typical symptoms of PSP are postural instability and falls,
cognitive decline, eye movement abnormalities [145_TD$DIFF] 24] On the
other hand CBS is associated with dystonic and myoclonic
symptoms, cortical dysfunction and alien limb syndromes,
sensory negligence, but also levodopa resistant rigidity [146_TD$DIFF] 25,26].
Interweaving of the symptoms of clinical cases is a challenge in
the diagnostic process of some patients. One of the studies
showed this combination of symptoms in a patient with pre-
mutations in the fragile Xmental retardation 1 gene (FMR1) [147_TD$DIFF] 27].
The case described in that work was symptomatically associat-
ed with the clinical manifestation of corticobasal syndrome
variant of progressive supranuclear palsy. Symptoms of this
patient also included early onset postural instability, echolalia,
oculomotor apraxia, increased latency of saccade initiation.
Cognitive impairment and behavioral abnormalities are
vital features of both CBS and PSP. Since the description of the
disease in 1960s, the aspect of deterioration in cognitive
abilities is discussed and perceived as an important factor in
the evolution of non-motor symptoms of CBS and PSP. Apathy,
disturbances in the executive function, memory and visuo-
spatial deﬁcits are only some factors of progressive symp-
tomatology of 4R tauopathies [148_TD$DIFF] 28]. In another study examining
patients suffering from PSP or CBS, the assessment of per-
formance of activities of daily living (ADL) led to a conclusion
that memory dysfunction is the most important functional
disability. The results of ADL analysis presented more
disabilities among patients with CBS than PSP [149_TD$DIFF] 29].
Research conducted by Dutt and coworkers presented the
evolution of atrophy in PSP and CBS over 6 and 12months [150_TD$DIFF] 30].
The study showed greater longitudinal atrophy rates of
cortical and basal ganglia regions among patients with CBS,
whereas midbrain and pontine atrophy did not change
signiﬁcantly with time. The study stressed the relevance of
MRI as a tool in combined 4R tauopathy clinical trials. It also
highlighted that PSP rating scale (PSPRS), though not intended
to examine CBS, is an element of clinical trial useful in
combined 4R trials due to the multidimensional resemblance
of CBS and PSP [151_TD$DIFF] 30,31].Differential diagnosis of diseases using imaging methods
such as positron emission tomography (PET) and SPECT reveal
varied regions of hypometabolism or decreased blood ﬂow
and denervation [152_TD$DIFF] 32]. I-FP-CIT-SPECT and F-Dopa PET present
symmetric striatal dopaminergic denervation in patients
with PSP and asymmetric striatal dopaminergic denervation
in patients with CBS. 99mTc-HMPAO-SPECT/FDG PET shows
hypometabolism in frontal lobe andmidbrain and asymmetric
hypometabolism in striatum and parietal cortex. I-BZM
differentiates symmetric in PSP with asymmetric in CBD
postsynaptical striatal degeneration.
CBS and PSP have also been analyzed in Polish literature. It
had been shown that CBS clinical presentation may become
a clinical manifestation of not only PSP pathology, but
also AD and Creutzfeldt-Jakob disease [153_TD$DIFF] 33] Though the review
classiﬁes potential morphological changes such as atrophy
of midbrain in PSP or cortical atrophy in CBS, imaging of
variants with mixed clinical presentation requires further
analysis [154_TD$DIFF] 33]. Multiple mechanisms of pathogenesis of the
disease make adequate examination more difﬁcult. It is
stressed that in the context of neuroimaging at early stages
of CBS, SPECT or PET may be more useful than MRI [155_TD$DIFF] 33,34].
Usefulness of SPECT and MRI in the context of atypical
parkinsonism had been described in 2003 [156_TD$DIFF] 35]. The study
stressed that PSP, CBS and also MSA are the most difﬁcult
to differentiate. It also highlighted low sensitivity of the
criteria which were then used. [156_TD$DIFF] 35]. Although new criteria of
PSP and CBS have been applied since 2003, the remaining
doubtful boundaries of the diseases still create an obstacle
in making a proper diagnosis. Multidimensional aspect of
PSP and CBS may also reduce the number of differentiating
factors.5. ConclusionTaking into account the background of the disease gained
from the interview, physical examination and additional
studies, all ﬁve patients were diagnosed with a neurodegen-
erative process with cognitive impairments and a parkinso-
nian syndrome most likely CBD-PSP. Patients with mixed
presentation of symptoms of diseases are difﬁcult to classify
to one group. This group of patients represents the most
conspicuous part of the analysis concerning primary tauo-
pathies with combined symptomatology. Further examina-
tion requires extended assessment of a larger group of
patients.
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